Payment overview · 2025
General Payments
$513.81
26 reported records · 9 companies
Healthcare provider profile · identity verified
Pankaj J Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · MIDLAND, TX · NPI 1124009766
Verified facts
What the public records show
CMS Open Payments records show Pankaj J Patel, M.D. received $513.81 in general payments during 2025 across 26 reported records.
Boston Scientific Corporation accounted for 41.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ofev.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ofev by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $212.65 | 41.4% | 12 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $106.47 | 20.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.01 | 7.6% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $38.39 | 7.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.86 | 6.2% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.67 | 5.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $23.05 | 4.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.50 | 4.0% | 1 | 2025 |
| 3B Medical, Inc. | Unresolved — no canonical attribution shown | $12.21 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $513.81 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $141.47 | 7 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $79.22 | 3 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $48.05 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $38.39 | 2 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $31.86 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $29.67 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $27.25 | 1 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| OptiCross Normalized: opticross |
Device | Boston Scientific Corporation | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| LUNA Normalized: luna |
Device | 3B Medical, Inc. | $12.21 | 1 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $5.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 90 | exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
153 | 57 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
49 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
149 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 382 | 137 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 373 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 277 | 89 |
| Atorvastatin Calcium | Atorvastatin Calcium | 248 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 70 |
| Prednisone | Prednisone | 247 | 133 |
| Losartan Potassium | Losartan Potassium | 158 | 50 |
| Symbicort | Budesonide/Formoterol Fumarate | 153 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 51 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 149 | 51 |
| Enalapril Maleate | Enalapril Maleate | 148 | 48 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 144 | 49 |
| Spiriva Respimat | Tiotropium Bromide | 136 | 52 |
| Gabapentin | Gabapentin | 134 | 41 |
| Lisinopril | Lisinopril | 132 | 42 |
| Azithromycin | Azithromycin | 127 | 90 |
| Furosemide | Furosemide | 120 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 40 |
| Metformin Hcl | Metformin Hcl | 108 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 36 |
| Ventolin Hfa | Albuterol Sulfate | 100 | 48 |
| Breo Ellipta | Fluticasone/Vilanterol | 97 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 40 |
| Eliquis | Apixaban | 90 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 27 |
| Simvastatin | Simvastatin | 78 | 24 |
| Omeprazole | Omeprazole | 77 | 25 |
| Potassium Chloride | Potassium Chloride | 75 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 71 | 63 |
| Incruse Ellipta | Umeclidinium Bromide | 67 | 20 |
| Donepezil Hcl | Donepezil Hcl | 66 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 23 |
| Alprazolam | Alprazolam | 54 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 54 | 13 |
| Glipizide Er | Glipizide | 51 | 19 |
| Sertraline Hcl | Sertraline Hcl | 51 | 17 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 49 | 47 |
| Ezetimibe | Ezetimibe | 48 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 19 |
| Carvedilol | Carvedilol | 47 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 11 |
| Clonidine Hcl | Clonidine Hcl | 44 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 37 |
| Arnuity Ellipta | Fluticasone Furoate | 42 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 14 |
| Farxiga | Dapagliflozin Propanediol | 40 | 13 |
| Januvia | Sitagliptin Phosphate | 39 | 13 |
| Jardiance | Empagliflozin | 38 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 14 |
| Levofloxacin | Levofloxacin | 35 | 28 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | 11 |
| Metformin Hcl Er | Metformin Hcl | 32 | 13 |
| Xarelto | Rivaroxaban | 31 | 11 |
| Memantine Hcl | Memantine Hcl | 30 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 15 |
| Amoxicillin | Amoxicillin | 24 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Fasenra Pen | Benralizumab | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Dulera | Mometasone/Formoterol | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | 11 |
| Pirfenidone | Pirfenidone | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Prevacid | Lansoprazole | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Letairis | Ambrisentan | 13 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Ofev | Nintedanib Esylate | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $513.81 · 26 records | Boston Scientific Corporation | AMVUTTRA, AVVIGO Guidance System, Arikayce, CAMZYOS, ELIQUIS, GLASSIA, General - Balloon Catheters, JASCAYD, LUNA, NUCALA, OFEV, OptiCross, ROTAPRO, TEZSPIRE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error